Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Cell Line
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266829
Gaucher disease is a rare genetic disorder characterized by the deposition of glucocerebroside in cells of the macrophage-monocyte system. The disorder results from the deficiency of the enzyme glucocerebrosidase.
IPSCIO Record ID: 204322
Licensor grants a license, with the right to sublicense, in accordance with the terms of the Trademark License Agreement, to use the Licensor Trademark(s) in such country(ies) in the Territory in connection with the making, having made, use, sale, offering for sale, importation, packaging, distributing and promoting of Product in the Field and in such country(ies) in the Territory.
Migalastat, trade name Galafold (formerly known as Amigal) is a drug for the treatment of Fabry disease, a rare genetic disorder. Amigal, is an orally-administered, small molecule pharmacological chaperone for the treatment of Fabry disease.
Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. Beginning in childhood, this buildup causes signs and symptoms that affect many parts of the body.
The specific treatment available for Fabry disease (FD) is enzyme replacement therapy (ERT) with agalsidase alfa or beta.
IPSCIO Record ID: 286096
Whereas, the remaining part of the Technology, known as the University Technology, is owned by the University and ownership of the Licensee Technology and the University Technology is governed by a separate agreement between the University and the Licensee,
The University is granting to the Licensee an exclusive license to the University Technology.
The University grants an irrevocable, exclusive right and license in any and all Fields of Use, including the right to sub license to Affiliates or unrelated third parties, to the Licensed Patents and the University Technology to make, have made, use, sell, offer to sell, import and export, lease or otherwise dispose of Licensed Product in the Territory.
The technology shall mean Licensees Technology and University Technology, including but not limited to, multipotent postnatal derived progenitor cells, precursors, progeny or components thereof, products and information obtained from the foregoing, processes and products utilized in production or processing of any of the foregoing, methods of utilizing any of the foregoing, and any Trade Secret Information or know-how relating to the foregoing. The term Technology shall also include any invention involving multipotent postnatal derived progenitor cells (a) that is the result of research conducted.
Licensed Patent shall mean a Patent that claims as an invention one or more aspects of the Technology.
Licensed Product shall mean any Technology which is within the scope of one or more claims of a Licensed Patent and, but for the license granted in this Agreement, would infringe, constitute contributory infringement, or constitute inducement to infringe of one or more such claims when made by, made for, used, sold, offered for sale, imported, exported, leased, or otherwise disposed of by the Licensee.
Lysosomal storage disorders are a group of more than 40 recessive genetic diseases resulting in deficiencies in lysosomal acid hydrolases. Although individually rare, lysosomal storage disorders have a prevalence of 1 per 7700 live births. Such diseases include Gaucher's disease, Fabry disease, Niemann-Pick disease, mucopolysaccharidoses Type I through VII, Tay-Sachs disease, among many others. Loss of lysosomal enzyme activity results in the progressive accumulation of undegraded substrate within the lysosomes, resulting in engorgement of the organelle, subsequent cellular, tissue, and organ dysfunction, and often death. Lysosomal storage diseases affect multiple organ systems, many of them before birth, resulting in irreversible defects. Clinical treatments for metabolic storage disorders are limited to bone marrow transplantation and enzyme replacement therapy.
IPSCIO Record ID: 6880
Taliglucerase alfa is used as an enzyme replacement therapy for the treatment of Gaucher disease. Taliglucerase alfa is our proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human cells that is mutated or deficient in patients with Gaucher disease.